Table 3.
HCV treatment outcomes among incarcerated HCV population
| No | Study | Country | Treatment regimen | Subjects treated | Predominant genotype | Outcomes |
||
|---|---|---|---|---|---|---|---|---|
| SVR (%) | Treatment completion (%) | Virological failure | ||||||
| 1 | Wong et al. [25] (2021) | Singapore | DAA & PR | 1,001 | GT3: 71%, GT1: 24% | 93.6 (ITT), 97.0 (PP) | 97 | 2.9 |
| 2 | Cuadrado et al. [21] (2018) | Spain | DAA | 69 | GT3: 41%, GT1: 23% | 92.4 (ITT), 95.3 (PP) | 97 | 4.4 |
| 3 | Pontali et al. [33] (2018) | Italy | DAA | 142 | GT1: 36%, GT3: 36% | 90.8 (ITT), 96.2 (PP) | 94 | 3.5 |
| 4 | Giuliani et al. [20] (2020) | Italy | DAA | 196 | GT1: 50%, GT3:35% | 57.1 (ITT) | NA | NA |
| 5 | Fiore et al. [36] (2021) | Italy | DAA | 84 | GT3: 45%, GT1: 33% | 97.6 (ITT) | 97.6 | 2.4 |
| 6 | Yang et al. [19] (2020) | Taiwan | DAA | 165 | GT6: 39%, GT1: 22% | 100 (ITT) | 100 | 0 |
| 7 | Overton et al. [23] (2019) | Australia | DAA | 698 | GT1: 53%, GT3: 42% | 61.5 (ITT), 92.0 (PP) | 92 | 7.9 |
| 8 | Papaluca et al. [18] (2019) | Australia | DAA | 416 | GT3: 50%, GT1: 44% | 72.4 (ITT), 96.0 (PP) | 88 | 2.8 |
| 9 | Bartlett et al. [31] (2018) | Australia | DAA | 98 | GT3: 59%, GT1: 36% | 65.2 (ITT), 97.0 (PP) | NA | 2 |
| 10 | Chan et al. [24] (2020) | USA | DAA | 248 | NA | 59 (ITT), 90 (PP) | 91 | NA |
| 11 | Hariri et al. [22] (2020) | Iran | DAA | 103 | GT3: 52%, GT1: 44% | 37 (ITT), 43 (PP) | 85 | NA |
| 12 | Hochstatter et al. [37] (2017) | USA | PR | 328 | NA | 56.7 | NA | NA |
| 13 | Allen et al. [38] (2003) | USA | PR | 90 | GT1: 43% | 29 | 45.6 | 32.2 |
| 14 | Aspinall et al. [14] (2016) | Scotland | PR | 291 | GT2/3: 62% | 60.5 | 73.5 | NA |
| 15 | Bate et al. [39] (2010) | Australia | PR | 74 | GT3: 51%, GT1: 24% | 72 | NA | NA |
| 16 | Boonwaat et al. [40] (2010) | Australia | PR | 185 | GT2/3: 55% | 27.6 | NA | 35.6 |
| 17 | Chew et al. [41] (2009) | USA | PR | 71 | GT1: 65% | 28.2 | 46.5 | NA |
| 18 | Juan et al. [42] (2014) | Spain | PR | 431 | GT1: 51%. GT3: 36% | 52.1 | 77.5 | NA |
| 19 | Farley et al. [43] (2005) | Canada | PR | 80 | GT1: 48%, GT3: 38% | 66.3 | 79.4 | NA |
| 20 | Iacomi et al. [44] (2013) | Italy | PR | 50 | GT1: 50% | 50 | 60 | 30 |
| 21 | Lloyd et al. [45] (2013) | Australia | PR | 108 | GT1: 54% | 44.0 (ITT), 69.0 (PP) | 69.4 | 12.3 |
| 22 | Maru et al. [46] (2008) | USA | PR | 68 | GT1: 75% | 47.1 | 69.1 | 17.6 |
| 23 | Rice et al. [47] (2012) | USA | PR | 234 | GT1: 63.4% | 42.9 | 75 | NA |
| 24 | Saiz de la Hoya et al. [48] (2014) | Spain | PR | 244 | GT1: 44%, GT3: 42% | 63.5 | 76.2 | 7.3 |
| 25 | Simonović Babić et al. [49] (2016) | Serbia | PR | 32 | GT3 | 62.5 | 87.5 | NA |
| 26 | Strock et al. [50] (2009) | Luxembourg | PR | 86 | GT3: 53% | 52.3 | 65.1 | 15.1 |
HCV, hepatitis C virus; SVR, sustained-virological response; DAA, direct-acting antivirals; PR, pegylated interferon and ribavirin; GT, genotype; ITT, intention-to-treat; PP, per-protocol; NA, not available.